Document is current

Article History

First Online: 21 November 2019

Compliance with Ethical Standards

:

: Alessia Fornoni is an investor on pending or issued patents (US 10,183,038 and US 10,052,345) aimed at diagnosing or treating proteinuric kidney diseases. She stands to gain royalties from the future commercialization of these patents. She is Chief Scientific Officer of L&F Health LLC and is a consultant for Variant Pharmaceuticals. Variant Pharmaceuticals has licensed worldwide rights from L&F Research to develop and commercialize hydroxypropyl-beta-cyclodextrin for the treatment of kidney disease. She is the founder of LipoNexT LLC. She is also supported by Roche and Boehringer Ingelheim.Michelle Ducasa and Alla Mitrofanova declare that they have no conflict of interest.

: This article does not contain any studies with human or animal subjects performed by any of the authors.